OPINION
I. INTRODUCTION
Before the Court are Defendants Gald-erma Laboratories, L.P. and Galderma Laboratories, Inc.’s Motion to Dismiss and Motion to Stay Pending the Outcome of the Administrative Proceeding, Plaintiff Thomas Skold’s Response in Opposition thereto, and Galderma L.P. and Galderma Inc.’s Reply, as well as Defendant Galder-ma S.A.’s Motion to Dismiss and Motion to Stay Pending the Outcome of the Administrative Proceeding, the Plaintiffs Response in Opposition thereto, and Galder-ma S.A.’s Reply.
For the reasons that follow, the motion to stay shall be denied as moot, the motions to dismiss for failure to state a claim shall be granted in part, and the motion to dismiss for lack of personal jurisdiction shall be denied.
II. FACTUAL HISTORY AND PROCEDURAL BACKGROUND
According to the facts alleged in the Complaint, Plaintiff Thomas Skold is a citizen of Sweden. Compl. ¶4. Defendant Galderma S.A. (“S.A.”) is a Swiss corporation with its principal place of business in Switzerland, while Defendant Galderma Laboratories, Inc. (“Inc.”) is a Delaware corporation with its principal place of business in Texas and Defendant Galderma Laboratories, L.P. (“L.P.”) is a Texas limited partnership with its principal place of business in Texas. Id. ¶¶ 5-7. All three Defendant entities are “involved in the research, development, marketing, and sale of pharmaceutical and therapeutic skin care products.” Id. Skold alleges that S.A. is the ultimate owner of both Inc. and L.P. Id. ¶ 8.
In Summer 2001, Skold began developing the technology that would eventually become known as “Restoraderm” and set out to find entities interested in licensing the technology and developing the resulting product to be marketed and distributed for mass consumption. Id. ¶ 11. In September 2001, Skold met with Collage-nex Pharmaceuticals, Inc. (“Collagenex”) of Newtown, Pennsylvania, and presented it formulations of his Restoraderm technology, using the phrase “Restoraderm technology” both in his oral presentation and written materials. Id. ¶ 12. Skold used the term “Restoraderm” in similar meetings he had with other pharmaceutical companies throughout the remainder of 2001. Id. ¶¶ 14-18. He first manufactured a Restoraderm product “in its current form in about October 2001,” and delivered samples of a material with the
In August 2004, Skold and Collagenex signed a Consulting Agreement under which Skold would provide “technical consulting and development services with respect to Restoraderm Technology in such manner as shall be requested by the Company from time to time,” defining “Resto-raderm Technology” as the “topical drug delivery technology developed by Skold.” Id. ¶ 28. On August 19, 2004, Skold and Collagenex restructured the 2002 Agreement into an Asset Purchase and Product Development Agreement (the “2004 Agreement”), which “formalized Skold’s control of the Restoraderm development.” Id. ¶¶ 27, 29. In the course of negotiating this agreement, Collagenex “confirmed” that the Restoraderm trademark was included in the assets contemplated in the agreement. Id. ¶ 30.
Inc. acquired Collagenex in March 2008 and terminated the 2004 Agreement with Skold on November 27, 2009. Id. ¶¶ 33-34. Section 8.5(b) of the 2004 Agreement provides that should Collagenex terminate the Agreement, the assets, including the Restoraderm intellectual property, and additional related records shall be transferred to Skold. Id. ¶ 35 & Ex. A at 19. Skold alleges that the “parties’ contractual intent was that the Restoraderm trademark would be returned to Skold if the 2004 Agreement were cancelled by Colla-genex (or its successors-in-interest),” but that the Defendants have yet to return the Restoraderm trademark to Skold in accordance with this provision. Id. ¶¶ 36-37.
After terminating the 2004 Agreement, Skold alleges the Defendants “gave mixed messages” regarding their intentions for future use of the Restoraderm trademark and Restoraderm technology. Id. ¶ 38. On September 14, 2010, L.P. issued a Press Release announcing the launch of “Cetaphil® Restoraderm® products” in the United States, which, according to the Complaint, “made it clear that the Defendants intended to use the mark ‘Restora-derm’ in connection with a product to be sold by them in the United States.” Id. ¶¶ 39-40. Skold alleges ' that this press release “was the first time that the Defendants had used the term ‘Restoraderm’ in connection with a U.S. product that did not involve Skold’s Restoraderm technology.” Id. ¶ 43.
Skold filed an action in this Court on September 15, 2014, alleging three counts under the Lanham Act — trademark infringement, false advertising, and unfair competition- — and three counts under Pennsylvania state law — unfair competition, breach of contract, and unjust enrichment. Id. ¶¶ 48-80. Skold previously initiated a proceeding before the U.S. Patent and Trademark Office seeking to cancel the Defendants’ registration of the “Resto-raderm” trademark, id. ¶ 37, but that proceeding has been stayed by the Trademark Trial and Appeal Board (“TTAB”) pending the outcome of this litigation. See infra Section IV.A.
L.P. and Inc. filed a motion to dismiss on December 1, 2014. They contend as follows. First, the breach of contract and unjust enrichment claims are barred by Pennsylvania’s four-year statute of limita
On December 22, 2014, Skold filed his response in opposition. He argues that he filed the Complaint within the four-year limitations period because he was unaware the contract was breached until September 14, 2010, when L.P. issued the press release announcing the Restoraderm product. In the alternative, Skold contends he is entitled to equitable tolling of the statute of limitations. Furthermore, he argues that the unjust enrichment claim is not precluded against all parties by the contract and the gist of the action doctrine does not bar his unfair competition claim. See Pl.’s L.P./Ine. Opp’n at 10-13. In reply, L.P. and Inc. argue that Skold knew about the Defendants’ use of Restoraderm no later than August 16, 2010, when he initiated the TTAB proceeding, attaching a May 26, 2010 press release “demonstrating Defendant’s widespread public use of the RESTORADERM mark for its products.” L.P./Inc. Reply at 2. Based on that press release, L.P. and Inc. contend that Skold “transparently] attempts] to avoid dismissal on statute of limitations grounds.” Id. They also argue that Skold is not entitled to equitable tolling and reaffirm their arguments on the other grounds. See id. at 4-8.
S.A. filed its own motion to dismiss on January 15, 2015. See S.A. Mot. to Dismiss; see also supra note 1. In opposition to S.A.’s jurisdictional argument, Skold argued that jurisdiction is proper under the federal long-arm statute, Federal Rule of Civil Procedure 4(k)(2), because S.A. has sufficient contacts with the United States such that the exercise of jurisdiction comports with due process. See Pl.’s S.A. Opp’n at 9-10. Furthermore, Skold alleges that the forum selection clause in the 2004 Agreement operates to subject S.A. to jurisdiction in this Court. See id. In Reply, S.A. argues that: (1) Rule 4(k)(2) does not apply; (2) the forum selection clause does not apply to S.A. as a non-signatory third party to the 2004 Agreement; and (3) the forum selection clause does not apply to the Skóld’s claims against it. See S.A. Reply at 2-9.
III. DISCUSSION
A. Motions to Stay
The Court first addresses the Defendants’ motions to stay this action pending a decision of the TTAB in the cancellation proceeding. In his Opposition to S.A.’s motion to dismiss and motion to stay, Skold brought to the Court’s attention that the TTAB proceeding has been stayed pending the outcome of this litigation. PL’s S.A. Opp’n at 11 (citing Michie Decl. ¶ 13 & Ex. J). In its Reply, S.A., on behalf of all three Defendants, recognized this action by the TTAB and withdrew the motions to stay. S.A. Reply at 1 n. 1. Accordingly, the Defendants’ motions to stay are moot.
B. Alternative Dispute Resolution Clause
The Defendants contend that the Complaint should be dismissed in its entirety for failure to comply with the 2004 Agreement’s dispute resolution and mediation clause. L.P./Inc. Mot. to Dismiss at 12-13.
The dispute resolution clause in the 2004 Agreement contains two clauses, one of which is mandatory (the parties shall refer the matter to senior executives to attempt to negotiate a resolution) and the other which is permissive (the parties may refer the matter to nonbinding mediation). Given the voluntary nature of the latter, this Court agrees with Skold that he was not required to refer this dispute to mediation before bringing suit here against Inc.
L.P. and S.A., who are not parties to the 2004 Agreement, also contend that the dispute resolution clause requires their dismissal from this action. In essence, they urge this Court to accept the contention that a nonparty to an agreement should be permitted to force a signatory party to engage in negotiations pursuant to a permissive mediation clause in that agreement as a condition precedent to filing suit but cite no relevant case or statute in support of this contention. See United States v. Benish,
Regarding Inc.: although Skold did fail to bring in a senior-level executive to try to resolve the dispute — as he was required to do under the dispute resolution provision — Inc.’s participation in the TTAB proceedings waived any rights it may have had to seek to have the parties’ executives negotiate an end to the dispute. See, e.g., LBL Skysystems (USA), Inc. v. APG-Am., Inc., No. 02-5379,
Viewing the four years’ worth of docket entries in the TTAB action, the Court considers that Inc. did not file a motion to stay the TTAB proceedings pending executive-level negotiations and instead filed, inter alia, motions to dismiss, a protective order, multiple summary judgment motions (one of which was partially granted in its favor), and a final brief in preparation for trial. See, e.g., Sköld v. Galderma Labs., Inc., Cancellation No. 92052897,
Moreover, the Court can look to the TTAB’s grant of partial summary judgment in favor of Inc. and dismissing Skold’s abandonment claim as a concrete example of an instance where Inc.’s conduct inconsistent with the dispute resolution clause caused prejudice to Skold, not to mention the expenditure of time, cost, and resources attendant to maintaining a multi-year trademark cancellation action. The Defendants have undisputedly accepted the judicial process and have demonstrated that fact by: (1) Inc.’s failure to raise the issue of good-faith negotiations promptly before the TTAB; (2) Inc.’s engaging in discovery in the TTAB action; (3) Inc.’s filing of several pretrial motions in the TTAB action, none of which raise the issue of negotiation; and (4) the Defendants’ decision to wait until the case was ready to proceed to trial before the TTAB and until a Complaint was filed in this Court before asserting Skold’s failure to negotiate as grounds for a motion to dismiss. See St. Clair Area Sch. Dist. Bd. of Educ. v. E.I. Assocs.,
Accordingly, the motions to dismiss on this ground shall be denied.
1. Timeliness of the Claim
The parties dispute whether Skold’s breach of contract claim in Count Five of the Complaint is barred by the statute of limitations. Absent a borrowing statute, a federal court exercising supplemental jurisdiction applies the forum state’s statute of limitations. Layser v. Morrison,
The Defendants argue that the claim for breach of contract began to accrue as early as November 27, 2009, when Inc. terminated the 2004 Agreement with Skold and did not immediately revert the Restoraderm intellectual property to Skold, as he alleges they were required to do. L.P./Inc. Mot. to Dismiss at 6. They further argue that Skold’s commencing of the TTAB proceeding on August 16, 2010, necessarily evinces his knowledge on that date that the Defendants had breached the contract by not reverting the Restoraderm trademark to Skold as provided for in the contract. Id. They point to an attachment to Skold’s petition in the TTAB proceeding: a May 26, 2010, article titled “Cetaphil Restora-DERM for extra dry skin and Eczema,” which stated that Cetaphil, an allegedly well-known Inc. brand, was planning to introduce a new line of skin care products called “RestoraDERM” in August 2010. L.P./Inc. Reply at 2 (quoting Rochford Decl. Ex. B at Ex. 8). Given Skold’s concession that the Defendants’ September 14, 2010, press release put him on notice of the breach of contract claim, they contend that the similarly worded May 26, 2010, article should have also put him on notice. Id. at 2-3. If they are correct, the cause of action for breach of contract accrued no later than August 16, 2010, when Skold filed his petition in the TTAB proceeding attaching the article, and this lawsuit is untimely because it was filed over four years and three months later. Id.
Whether they are correct is determined by reference to the so-called “Third Circuit Rule,” which “permit[s] a limitations defense to be raised by a motion under Rule 12(b)(6) ‘only if the time
“To decide a motion to dismiss, courts generally consider only the allegations contained in the complaint, exhibits attached to the complaint and matters of public record.” Id. (quoting Pension Benefit Guar. Corp. v. White Consol. Indus., Inc.,
Here, the bar is not apparent on the face of the Complaint. Accepting all facts alleged in the Complaint as true, see Fowler v. UPMC Shadyside,
The Defendants urge this Court to consider a document attached to Skold’s petition initiating the proceeding before the TTAB: a May 26, 2010, document L.P. and Inc. describe as a “release,” comparing it directly to the September 14, 2010, press release Skold alleges forms the basis for the breach of contract action. See L.P./Inc. Reply at 3. They argue that this document, titled “Cetaphil RestoraDERM for extra dry skin and Eczema,” contains all the information Skold needed to ascertain his injury and thus the claim for breach of contract is untimely. Id. “While this may be true, these materials may not be considered at the motion to dismiss stage. They are not integral to the complaint — the complaint was not ‘based’ on” this third-party document, but rather on the September 14, 2010, press release published by the Defendants. Schmidt, 770
Thus, taking the well-pleaded allegations in the Complaint as true, and drawing all reasonable inferences in Skold’s favor therefrom, the Court will not dismiss the contract claims on statute of limitations grounds, at least at this stage of the proceedings. Accordingly, the motions to dismiss the breach of contract claim in Count Five on this ground shall be denied.
2. Whether S.A. is a Prpper Defendant
S.A. contends that the breach of contract claim should be dismissed against it because Skold does not allege that it was a party to the 2004 Agreement. S.A. Mot. to Dismiss at 11; S.A. Reply at 2-3.
Even so, the only allegations in the Complaint concerning S.A.’s relationship with Inc., the successor-in-interest to the signatory party are so sparse as to warrant a dismissal of the contract claim against S.A. Paragraph 8 provides, “Upon information and belief, Galderma S.A. is the ultimate owner of Galderma Laboratories, Inc. and Galderma Laboratories, L.P.” Compl. ¶ 8. And paragraph 9 states simply, that “[e]aeh defendant acted in concert and active participation with each other in committing the wrongful acts alleged herein.” Id. ¶ 9. Notwithstanding the fact that paragraph 9 is conclusory, and, without more, is not entitled to any credence under Twombly and Iqbal, the single allegation in paragraph 8 that S.A. is the ultimate owner of Inc. is insufficient to hold S.A. liable for a breach of contract. See Ashcroft v. Iqbal,
D. Unjust Enrichment
The Defendants argue that Skold fails to state a claim for unjust enrichment. They contend the claim should be dismissed because it is precluded by the 2004 Agreement. This Court agrees that the existence of the 2004 Agreement precludes Skold from proceeding on an unjust enrichment claim against Inc., the successor-in-interest to the original Collagenex contract. See Hershey Foods Corp. v. Ralph Chapek, Inc.,
The same is not so for S.A. or L.P. S.A. argued throughout its briefing that it is not a party to the contract and that this Court should dismiss the breach of contract claims against it based on that fact, and the Court agreed. See supra subsection IV.C.2. However, because the relationship between Skold and S.A. is not governed by an express written agreement, S.A. cannot rely on the existence of the 2004 Agreement to shield it from Skold’s unjust enrichment claim. “ ‘Unjust enrichment’ is essentially an equitable doctrine,” under which “the law implies a contract which requires the defendant to pay to the plaintiff the value of the benefit conferred.” Mitchell v. Moore,
[1] benefits conferred on one party by another; [2] appreciation of such benefits by the recipient; and [3] acceptance and retention of such benefits under such circumstances that it would be. inequitable [or unjust] for defendant to retain the benefit without payment of value.
Premier Payments,
Skold’s allegations support a pri-ma facie case for unjust enrichment. As to the first element, he alleges that he has conferred benefits on the Defendants as a result of their use of the Restoraderm trademark in marketing and selling prod
Based on the allegations in the Complaint, Skold has plausibly stated a claim for unjust enrichment against S.A. and L.P. Accordingly, the motion to dismiss the unjust enrichment claim for failure to state a claim against S.A. and L.P. shall be denied.
E. Unfair Competition
The Defendants contend that Skold’s unfair competition claim should be dismissed because of the gist of the action doctrine, which bars plaintiffs from recovering under tort theories for failure to perform a contract. See L.P./Inc. Mot. to Dismiss at 8; see also Jones v. ABN Amro Mortg. Grp., Inc.,
The doctrine “forecloses a party’s pursuit of a tort action for the mere breach of contractual duties ‘without any separate or independent event giving rise to the tort.’ ” Brown & Brown, Inc. v. Cola,
(1) arising solely from a contract between the parties; (2) where the duties allegedly breached were created and grounded in the contract itself; (3) where the liability stems from a contract; or (4) where the tort claim essentially duplicates a breach of contract claim or the success of which is wholly dependent on the terms of a contract.
eToll, Inc. v. Elias/Savion Advertising, Inc.,
If the facts of a particular claim establish that the duty breached is one created by the parties by the terms of their contract — ie., a specific promise to do something that a party would not ordinarily have been obligated to do but for the existence of the contract — then the claim is to be viewed as one for breach of contract. If, however, the facts establish that the claim involves the defendant’s violation of a broader social duty owed to all individuals, which is imposed by the law of torts and, hence, exists regardless of the contract, then it must be regarded as a tort.
Id. at 68 (citations omitted).
Under Bruno, cases where tort actions are permitted to arise in the context of a contractual relationship are cases in which the defendant’s alleged acts are “not founded on the breach of any of the specific executory promises which comprise the contract.”
However, to the extent that Skold bases his unfair competition claim on the Defendants’ actions and communications after they chose not to revert the Restoraderm trademark, the Court finds that these allegations plausibly state an unfair competition claim that is not barred by the gist of the action doctrine. The Court recognizes the existence of some broader social duties at play in the law of unfair competition. The “gist of the action” of an unfair competition claim “lies in the deception practiced in ‘passing off the goods of one for that of another,” and moreover, “the ‘underlying principle of law of unfair competition is to prevent substi
Accordingly, the motion to dismiss the unfair competition claim shall be denied.
F. Personal Jurisdiction Over Gald-erma S.A.
Skold contends that this Court may exercise personal jurisdiction over S.A. on the Lanham Act Claims pursuant to the federal long-arm statute, Federal Rule of Civil Procedure 4(k)(2). PL’s S.A. Opp’n at 9-10. Furthermore, he contends that the forum selection clause in the 2004 Agreement subjects S.A. to jurisdiction in this Court. Id. at 6-8. S.A. counters that it is not subject to jurisdiction under Rule 4(k)(2) because it does not have sufficient contacts with the United States as a whole to satisfy that Rule’s requirements and because Skold fails to properly allege Lan-ham Act claims against it. S.A. Reply at 4-9. S.A. rejects Skóld’s claim that this Court has jurisdiction over S.A. under the forum selection clause, because, it argues, the breach of contract claim is time-barred
1. Rule 4(k)(2)
The Due Process Clause of the Fourteenth Amendment to the Constitution permits personal jurisdiction so long as the nonresident defendant has certain minimum contacts with the forum such that maintenance of the suit does not offend “ ‘traditional notions of fair play and substantial justice.’ ” Int’l Shoe Co. v. Washington,
The Rule applies “in a narrow band of cases in which the United States serves as the relevant forum for a minimum contacts analysis.” Glencore Grain Rotterdam B.V. v. Shivnath Rai Harnarain Co.,
(A) the defendant is not subject to jurisdiction in any state’s courts of general jurisdiction; and
(B) exercising jurisdiction is consistent with the United States Constitution and laws.
Fed.R.Civ.P. 4(k)(2). In other words, for a Court to constitutionally exercise personal jurisdiction over a foreign defendant under the Rule: (1) there must be a claim arising under federal law; (2) the defendant must be beyond the jurisdictional reach of any state court of general jurisdiction; and (3) the defendant must have i sufficient contacts with the United States as a whole so that the court’s exercise of personal jurisdiction over the defendant comports with the due process requirements of the Constitution or other federal law. Saudi v. Acomarit Maritimes Servs., S.A.,
S.A. argues that Skóld has not alleged that S.A. has sufficient minimum contacts with the United States as a whole to satisfy the Rule 4(k)(2) test. Skóld counters that the standard to be followed in analyzing satisfaction of the third prong “is similar to that of personal jurisdiction for a particular state: ‘general jurisdiction is available when the .defendant’s contacts unrelated to the litigation are continuous and systematic,’ ” and proffers that S.A.’s' website states that S.A. maintains a Research and Development facility in the United States, claiming that the existence of this facility is sufficient to satisfy this prong. Pl.’s S.A. Opp’n at 10 (quoting BP Chemicals,
To the extent Skold invokes the standard governing the exercise of general personal jurisdiction over a nonresident corporate defendant, this Court very recently explained in Farber v. Tennant Truck Lines, Inc.,
Goodyear and Daimler “make clear that even a company’s ‘engagement] in a substantial, continuous and systematic course of business’ is alone insufficient to render it at home in a forum.” Farber,
Here, even assuming arguendo that S.A. does own and operate a single research and development facility in the United States, as Skold contends (and S.A. denies, see S.A. Reply at 8), that fact is insufficient to render S.A. “essentially at home” in the United States. See BP Chemicals,
2. Forum Selection Clause
Personal jurisdiction is, however, a waivable right, and litigants can give “express or implied consent to the personal jurisdiction of the court” through a “variety of legal arrangements,” including forum selection clauses in contracts executed by the parties. Ins. Corp. of Ir., Ltd. v. Compagnie des Bauxites de Guinee,
And this is Skóld’s final potential avenue for this Court to have personal jurisdiction over S.A.: the forum selection clause found in section 9.10 of the 2004 Agreement. The section reads, in relevant part:
Each Party hereby submits itself for the purpose of this Agreement and any controversy arising hereunder to the exclusive jurisdiction of the state and federal courts.located in the Commonwealth of Pennsylvania, and any courts of appeal therefrom, and waives any objection on the grounds of lack of jurisdiction (including, without limitation, venue) to the exercise of such jurisdiction over it by any such courts.
Compl. Ex. A § 9.10. The Court must make two inquiries in determining the clause’s applicability to its jurisdictional analysis here: first, whether the forum selection clause binds S.A. as a non-signatory third party, and, second, whether the claims Skóld alleges against S.A. arise out of the agreement and are thus governed by its terms.
a. Whether the clause binds S.A.
Nonsignatory third parties who are “closely related” to a contractual relationship are bound by the forum selection clauses contained in the agreements underlying that relationship. See, e.g., AAMCO Transmissions, Inc. v. Romano,
The Court may apply the forum selection clause to a nonsignatory if the totality of the circumstances, makes it fair and reasonable to bind the nonsignatory to the clause because it is foreseeable to the non-signatory that it would become involved in the contract dispute. Lefkowitz v. McGraw-Hill Cos., No. 13-1661,
Skóld alleges that S.A. is the owner of Inc., the successor-in-interest to Col-lagenex (the original signatory). Compl. ¶ 8. He also alleges that S.A. has received a direct benefit from the agreement: according to the Complaint, S.A. has “taken the fruits of the Skóld-Collagenex contract — the trademark and related goodwill associated with the Restoraderm® name— and used those assets in the marketing and sale of its Cetaphil® products.” PL’s S.A. Opp’n at 8. See Synthes, Inc. v. Emerge Med., Inc.,
It is certainly plausible from the totality of the circumstances alleged that S.A. was closely related to the contractual relationship between Skóld and Inc. As a nonsig-natory, it gained a benefit from the use of a trademark that was transferred to its subsidiary (as successor-in-interest) via a contract between the plaintiff and the subsidiary’s predecessor-in-interest. Given its engagement, in the marketing and sale of the Cetaphil/Restoraderm product, it also should reasonably have foreseen becoming involved in the relevant dispute over the Defendants’ alleged refusal to revert the trademark back to Skóld after Inc. terminated the 2004 Agreement and after S.A. continued to register and use the very trademark at issue in marketing and selling its products. Thus, the Court finds it eminently fair and reasonable that the forum selection clause binds S.A. as a non-signatory party.
S.A. argues that the law requires the non-signatory foresee “being sued on the contract itself.” S.A. Reply at 4 (emphasis in original). In support of this argument, it includes a truncated quote from Burtch v. Security Pacific Bank Oregon (In re Mushroom Transportation Co.), to the effect that to demonstrate the “foreseeability [ ] required to enforce such a clause against a nonparty to an agreement” a plaintiff must establish that the nonsigna-tory “should have foreseen governance by the clause.”
This is only the first part of the analysis, however; the Court yet may be unable to enforce the forum selection clause and exercise jurisdiction over S.A. if the claims Skold alleges do not “arise under” the 2004 Agreement.
b. Whether the clause applies to Skold’s claims against S.A.
Forum selection clauses are treated as ordinary contract provisions and are subject to the ordinary rules of contract interpretation. See M/S Bremen v. Zapata Off-Shore Co.,
The Third Circuit’s decision in Crescent International v. Avatar Communities, Inc.,
Crescent argued on appeal that the forum selection clause was narrowly drafted and could not apply to noncontractual claims. The Third Circuit, however, determined that the pleading of alternate non-contractual theories does not alone allow a party to avoid enforcement of a forum selection clause “if the claims asserted arise out of the contractual relation and implicate the contract’s terms.” Id. at 945. The court held that the district court correctly construed the forum selection clause, concluding that “[although only one of Crescent’s claims is based on a breach of contract theory, all of them involve allegations arising out of the agreement implicating its terms.” Id.; see also Coastal Steel Corp. v. Tilghman Wheelabrator Ltd.,
Several decisions involving similarly worded forum selection clauses in similar factual scenarios from courts in other jurisdictions are also helpful in resolving this question. In Omron Healthcare, Inc. v. Maclaren Exports Ltd.,
Taking into account the above analysis, the Court finds that the forum selection clause in the 2004 Agreement applies to Skóld’s claims against S.A. Those claims arise out of the 2004 Agreement and implicate its terms. See Crescent,
The “nucleus” of the 2004 Agreement is the transfer of the Restoraderm trademark, and the “spirit of the ... agreement contemplate^] the rights and duties of the parties” concerning the Restoraderm trademark. Laserdynamics,
At bottom, because “all disputes the resolution of which arguably depend on the construction of an agreement ‘arise out of that agreement” for purposes of enforcing a forum selection clause, Omron,
The exercise of personal jurisdiction over S.A. is proper.
An appropriate Order follows.
Dated: March 20, 2015.
REVISED ORDER
AND NOW, this 17th day of April, 2015, upon consideration of Defendants Galder-ma Laboratories, L.P. and Galderma Laboratories, Inc.’s Motion to Dismiss and Motion to Stay Pending the Outcome of the Administrative Proceeding [ECF No. 22], Plaintiff Thomas Skold’s Response in Opposition thereto [ECF No. 29], and Galderma L.P. and Galderma Inc.’s Reply [ECF No. 33]; Defendant Galderma S.A.’s Motion to Dismiss and Motion to Stay Pending the Outcome of the Administrative Proceeding [ECF No. 36], the Plaintiffs Response in Opposition thereto [ECF
(1) Defendant Galderma S.A.’s motion to dismiss the breach of contract claim in Count Five is GRANTED; Count Five of the Complaint shall be DISMISSED WITH PREJUDICE . as to Defendant Galderma S.A.;
(2) Defendants’ Galderma Laboratories, Inc.’s motion to dismiss the unjust enrichment claim in Count Six is GRANTED; Count Six of the Complaint shall be DISMISSED WITH PREJUDICE as to Defendant Galderma Laboratories, Inc.;
(3) Defendants’ motions to dismiss the unfair competition claim in Court Four are GRANTED IN PART; to the extent the Plaintiff bases his unfair competition claim on the Defendants’ alleged failure to revert the trademark to him based on the terms of the parties’ agreement, the claim is DISMISSED WITH PREJUDICE as to all Defendants on those grounds; the motions to dismiss this claim are otherwise DENIED;
(4) Defendants’ motions to dismiss for failure to state a claim are otherwise DENIED;
(5) Defendants’ motions to stay are DENIED AS MOOT; and
(6) Defendant Galderma S.A.’s motion to dismiss for lack of personal jurisdiction is DENIED.
Notes
. Galderma S.A. was served after Galderma Laboratories, L.P. and Galderma Laboratories, Inc. had filed their motion to dismiss. Galderma S.A. then filed its own motion to dismiss, incorporating the arguments contained in L.P. and Inc.'s motion to dismiss Skold's state-law claims and also arguing separately that this Court cannot exercise either general or specific personal jurisdiction over it. See S.A. Mot. to Dismiss at 11. Hereinafter, any reference in this Opinion to an argument made by “the Defendants” collectively will be used in the context of an argument asserted by Galderma Laboratories, L.P. and Galderma Laboratories, Inc. in their Motion to Dismiss that was later incorporated by Galderma S.A. in its Motion to Dismiss.
. Both cases the Defendants cite ostensibly in support of their argument are inapposite, as both involved parties to an agreement forcing other parties to that agreement to engage in the binding arbitration to which they assented at the time of contracting. See Seus v. John Nuveen & Co.,
. As an alternative to dismissal, the Defendants request that the Court stay this action and order that Skóld take the steps outlined in the dispute resolution clause before proceeding here. L.P./Inc. Mot. to Dismiss at 13 n. 5. In support of this argument, they cite Mendez v. Puerto Rican International Cos.,
. The Court finds no merit in the Defendants’ argument that the breach accrued on the day Inc. terminated the 2004 Agreement. Section 8.2 of the Agreement expressly provided that Collagenex could terminate at any time after March 31, 2007. See Compl. Ex. A. Construing all reasonable inferences in the Plaintiff’s favor, the Agreement was unclear by what date Inc. was required to transfer assets to Skold after electing to terminate the Agreement. Any arguments to the contrary involve fact-specific issues of contract interpretation not appropriate for determination at this stage of the proceedings.
. The Defendants also urged the Court at oral argument to consider the fact of the Plaintiff’s filing of the TTAB petition as evidence that he was aware the contract was breached prior to September 14, 2010. While the Complaint mentions that there was a TTAB proceeding pending at the time of filing, see Compl. ¶ 37, the date of filing is not included and thus the Court need not consider it in ruling on whether to grant a motion to dismiss the breach of contract claim on timeliness grounds, which, again, is only permissible ”[i]f the bar is ... apparent on the face of the complaint.” Schmidt,
. As the Court has denied the Defendants’ motion to dismiss on timeliness on the face of the Complaint, it declines to address Skold's equitable tolling argument.
.S.A. argues (but only in passing) in its Reply that L.P. likewise is not a party to the contract and should likewise not be called to defend against the breach claims. S.A. Reply at 2. This is not an argument that was raised by L.P. in its briefing, however, and the Court thus declines to address such an argument now. See Carpenter v. Vaughn,
. The Defendants also argue that the unjust enrichment claim is untimely because the Complaint was filed beyond the four-year statute of limitations. L.P./Inc. Mot. to Dismiss at 6-8. Skold repeats the arguments he raised in the breach of contract context. Pl.’s L.P./Inc. Opp'n at 10-12. The Court finds, for the purposes of this motion to dismiss, that the unjust enrichment claim similarly is not barred by the statute of limitations.
. At the Preliminary Pretrial Conference held on March 17, 2015, the Court ordered the parties to submit supplemental briefing on Skold’s unfair competition claim in light of the .Pennsylvania Supreme Court’s recent decision in Bruno. See ECF No. 48. That briefing having been provided, the Court will now rule on this claim.
. See, e.g., Williams v. Hilton Group PLC,
. The Court has already addressed the merits of the statute of limitations argument and denied the Defendants' motion to dismiss on that ground. See supra subsection IV.C.l. It will not reiterate the discussion here.
. At the outset, the Court recognizes the restrictive “arising under” language present in the 2004 Agreement's forum selection clause. Several courts have held that the term “relating to” in a clause casts a wider net than the term “arising out of” or "arising under,” and thus drawing analogies to other cases "is useful only to the extent those other cases address contact language that is the same or substantially similar.” John Wyeth & Bro. Ltd. v. CIGNA Int’l Corp.,
. In its Reply brief and at oral argument, . S.A. advanced the argument that "even if the 2004 Agreement's forum selection clause were somehow to apply to Galderma S.A., Skold ignores that he still needs to meet the constitutional minimum contacts test...." S.A. Reply at 4. This argument is meritless. The forum selection clause is one of the “variety of legal arrangements” through which parties impliedly consent to the personal jurisdiction of a particular court. See Insurance Corp. of Ireland,
